Prothena Shares Outstanding 2011-2021 | PRTA

Prothena shares outstanding from 2011 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Prothena Annual Shares Outstanding
(Millions of Shares)
2020 40
2019 40
2018 40
2017 38
2016 34
2015 30
2014 25
2013 19
2012 15
2011 14
2010 14
Prothena Quarterly Shares Outstanding
(Millions of Shares)
2021-09-30 51
2021-06-30 47
2021-03-31 40
2020-12-31 40
2020-09-30 40
2020-06-30 40
2020-03-31 40
2019-12-31 40
2019-09-30 40
2019-06-30 40
2019-03-31 40
2018-12-31 40
2018-09-30 40
2018-06-30 40
2018-03-31 39
2017-12-31 38
2017-09-30 38
2017-06-30 38
2017-03-31 36
2016-12-31 34
2016-09-30 34
2016-06-30 34
2016-03-31 34
2015-12-31 30
2015-09-30 31
2015-06-30 31
2015-03-31 27
2014-12-31 25
2014-09-30 27
2014-06-30 23
2014-03-31 23
2013-12-31 19
2013-09-30 18
2013-06-30 18
2013-03-31 18
2012-12-31 15
2012-09-30 14
2012-06-30 14
2012-03-31 14
2011-12-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.842B $0.001B
Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson's disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer's disease. Prothena Corporation plc is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69